Synergal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synergal

Quick Facts

Property Description
Active Ingredients Amoxicillin and Clavulanic Acid
Form Tablets, Oral Suspension
Pharmacological Class Beta-lactam/Beta-lactamase Inhibitor combination
Common Use Treating bacterial infections
Origin Semi-synthetic

What Type of Medicine is Synergal?

Synergal is classified as a combination prescription antibiotic that functions as a beta-lactam/beta-lactamase inhibitor, used against bacterial infections. This dual-component drug is a modernized, semi-synthetic derivative of the penicillin class, representing the formulation known internationally as Co-amoxiclav.

The Amoxicillin and Clavulanic Acid combination is clinically recognized for its essential role in medicine and is included on the World Health Organization's (WHO) List of Essential Medicines. It is considered a necessary component for public health and the effective treatment of various bacterial infections. As a prescription-only medicine, Synergal is tailored for oral administration, commonly available in tablets and as a powder for preparing an oral suspension suitable for both adults and children. This formulation is distinct from single-agent penicillins because it preemptively addresses bacterial resistance.

Composition: Why is Synergal Made of Two Active Ingredients?

Synergal is formulated with two active ingredients: Amoxicillin, the primary antibacterial agent, and Clavulanic Acid, which is a dedicated enzyme inhibitor. This fixed-dose pairing is engineered to counteract the common defense mechanisms of bacteria.

The Amoxicillin component works to kill bacteria by interfering with their cell wall development. The essential role of Clavulanic Acid is to protect the Amoxicillin from destruction by bacterial beta-lactamase enzymes, which is a leading mechanism of antimicrobial resistance. This combination has been the subject of extensive pharmacological studies, confirming that the synergistic presence of Clavulanic Acid expands the efficacy of Amoxicillin against resistant organisms.

What is the General Purpose of Synergal?

The general purpose of Synergal is to successfully treat bacterial infections by protecting the key antibiotic component from enzymatic destruction. The presence of Clavulanic Acid ensures the Amoxicillin can remain effective, providing a reliable, broad-spectrum therapeutic option.

By neutralizing the bacterial defense system, the drug combination maintains potency against various organisms that have developed resistance to the single-agent antibiotic. This synergistic action allows it to be a key tool in resolving common and persistent bacterial infections, such as those affecting the respiratory or urinary tracts.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Synergal?

Possible Side Effects and Safety Information

Official safety documentation for Synergal highlights the risk of disabling and potentially irreversible side effects. These serious risks can affect multiple body systems and may occur rapidly, within hours to weeks of initiating treatment, and in some cases, may persist after discontinuation.


Serious and Clinically Significant Adverse Reactions

Black Box Warning: The most prominent regulatory warning advises of the potential for combined serious side effects involving the tendons, muscles, joints, nerves, and the central nervous system.

System-Organ Class Serious Adverse Reaction Examples (Regulatory Focus)
Musculoskeletal Tendinitis and tendon rupture (Achilles tendon most common), muscle pain, joint pain/swelling.
Nervous System Peripheral neuropathy (numbness, tingling, burning pain, weakness, or pins and needles sensation in the limbs), seizures, altered mental status, confusion.
Psychiatric Anxiety, depression, memory impairment, disorientation, hallucinations, and suicidal thoughts or actions.
Cardiovascular Aortic aneurysm and dissection (a tear in the wall of the aorta).

Population-Specific Considerations: Patients over 60 years of age, those with kidney impairment, or those receiving corticosteroid therapy may have an increased risk of tendon damage. Use is typically reserved for patients with severe infections or those who have no alternative treatment options for certain milder conditions, such as acute bacterial sinusitis or uncomplicated urinary tract infections.


Common Adverse Reactions

The most commonly reported side effects include gastrointestinal effects like nausea and diarrhea, as well as headache, dizziness, and difficulty sleeping.


Regulatory Safety Summary: The authoritative safety profile dictates that treatment should be immediately stopped upon the first sign of a serious reaction—such as tendon pain, muscle weakness, or a change in sensation or mood—to minimize the risk of potentially irreversible effects. Safety monitoring also includes attention to disturbances in blood glucose and signs of hypersensitivity.

Overdose and Emergency Response

Overdosage with Synergal (Amoxicillin and Clavulanic Acid) is often described in official regulatory documents as generally asymptomatic or presenting with mild manifestations. The most frequently documented clinical signs are gastrointestinal symptoms, including diarrhea, vomiting, and stomach pain, and may also involve sleepiness.

However, official labeling highlights the specific risk of Amoxicillin crystalluria following high doses, which is the precipitation of drug crystals in the urinary tract. This is a critical, documented finding because it may lead to severe outcomes, including renal failure. Patients with pre-existing impaired renal function are identified in regulatory text as having a greater risk of toxic reactions, such as crystalluria and convulsions, which are documented neurological effects of overdosage.

Because of the potential for severe, documented complications, immediate medical attention must be sought for any suspected overdose. Emergency services should be called immediately if severe symptoms such as a seizure or trouble breathing occur. Management involves symptomatic treatment and supportive measures, particularly maintaining adequate fluid and electrolyte balance to minimize the risk of crystalluria. Haemodialysis is a documented procedure that can remove the drug components from the bloodstream, and no specific antidote is known.

Therapeutic Uses of Synergal

Quick Facts: Synergal

  • Therapeutic Domain: Used to manage chronic inflammatory conditions.
  • Primary Benefit: Supports sustained symptom management and may help reduce disease activity.
  • Associated Use: Included as part of a comprehensive long-term treatment strategy.

Synergal is an approved prescription medication utilized in the management of certain chronic inflammatory conditions. Its primary function is to help modulate the biological pathways involved in inflammation and immune system response, thereby supporting the therapeutic aims of the treatment plan. It is included as an option to help patients achieve and maintain control over disease symptoms.

The medication is designed to address the progression of the condition and is associated with a potential to aid in achieving sustained periods of low disease activity or remission. For patients with identified disease markers, Synergal may serve as a valuable component of combination therapy, often employed in conjunction with other established treatments to optimize outcomes.

As with all approved medicines, the use of Synergal is intended to be administered under the direction of a healthcare professional. Comprehensive details on the approved uses and safety profile are available in official medication resources.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility and Contraindications for Synergal

Synergal (Amoxicillin and Clavulanic Acid) is subject to strict eligibility rules set by regulatory authorities to manage patient risk, primarily concerning allergic history and organ function. The medicine is contraindicated in specific patient populations:

  • Prior Hypersensitivity: Individuals with a history of a serious allergic reaction (hypersensitivity) to any penicillin or other beta-lactam antibacterial drugs (e.g., cephalosporins) must not use this medicine.
  • Hepatic History: Patients with a previous history of cholestatic jaundice or hepatic dysfunction specifically associated with prior use of Amoxicillin/Clavulanic Acid are excluded from eligibility.

Use is restricted or conditional for other populations:

Population Group Regulatory Status
Severe Renal Impairment Restricted use; specific formulations (e.g., extended-release tablets) are contraindicated if creatinine clearance is <30 mL/min.
Infectious Mononucleosis Avoidance is recommended due to a high risk of developing a generalized skin rash.
Pediatric Use Use is not established for infants under three months of age in some formulations.
Pregnancy/Lactation Use is permitted only if clearly needed after risk assessment; caution is advised during breastfeeding as the components are excreted in milk.

These constraints ensure that the use of Synergal is limited to populations where the benefit outweighs officially documented risks, as defined by government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation confirms several interaction patterns for Synergal, a combination of Amoxicillin and Clavulanic Acid, primarily concerning changes in drug clearance and effects on blood coagulation.

Documented Interaction Patterns

Classification Type Interacting Substance Officially Documented Outcome
Renal Clearance Probenecid Co-administration is not recommended; it decreases the renal tubular secretion of Amoxicillin, resulting in increased and prolonged plasma concentrations of Amoxicillin.
Exposure Modification Methotrexate Amoxicillin may reduce the renal clearance of methotrexate, leading to an increase in its serum concentration and potential toxicity.
Pharmacodynamic Oral Anticoagulants (e.g., Warfarin) Concurrent use may result in an abnormal prolongation of prothrombin time, requiring appropriate coagulation monitoring.

Administration requirements are also noted: the medicine is recommended for administration at the start of a meal to enhance the absorption of the clavulanate component. Additionally, co-administration with Allopurinol is officially associated with an increased incidence of skin rash. Official labeling also notes that the use of this medicine is discouraged in patients with infectious mononucleosis due to a high incidence of rash.

Mechanism of Action

Irreversible Lysis through Cell Wall Disruption

The core mechanistic action of the Amoxicillin component is to target bacterial Penicillin-Binding Proteins (PBPs), enzymes essential for the final cross-linking phase of bacterial cell wall synthesis. By irreversibly inhibiting these enzymes, the cell wall cannot be properly completed, which causes the bacterial cell structure to destabilize. This molecular cascade leads to the sudden rupture and death (lysis) of the target bacteria.

Functional Synergy and Defense Neutralization

The second mechanism, provided by Clavulanic Acid, is purely protective. It functions as a "sacrificial" inhibitor that specifically and permanently binds to bacterial x0008eta-lactamase enzymes. This action neutralizes the bacterial defense system, restoring Amoxicillin's access to its PBP targets. The synergistic effect ensures the primary bactericidal mechanism can proceed against bacterial strains that possess this resistance mechanism.

Mechanistic Constraints and Pathway Limitations

The drug's mechanism is biologically constrained against certain types of bacterial resistance. This failure of action occurs when resistance arises from physical changes to the PBP targets or from the presence of x0008eta-lactamase classes that are not susceptible to Clavulanic Acid's inhibitory action, thereby preventing the induction of the lethal physiological effect.

Dosage and Administration Information

The administration of Synergal (Amoxicillin and Clavulanic Acid) is governed by official prescribing rules detailing the route, schedule, and duration of use. Synergal is approved for both oral administration, using tablets or reconstituted suspension, and for intravenous (IV) administration in a hospital setting.

Oral formulations must be taken at the start of a meal to enhance the absorption of the clavulanic acid component and minimize gastrointestinal intolerance. Dosing typically follows an every 8-hour or 12-hour schedule, depending on the specific tablet strength (e.g., 500 mg/ 125 mg or 875 mg/ 125 mg) and the total dose prescribed. The course of therapy should generally not exceed 14 days without a full clinical re-evaluation. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped; doses must not be doubled.

Official instructions mandate specific dose adjustments for patients with renal impairment. The dose and frequency must be modified based on the patient's Creatinine Clearance (CrCl), and high-dose extended-release forms are typically restricted for use in patients with CrCl < 30 mL/ min. Due to differences in the ratio of active ingredients, certain strengths and dosage forms are not interchangeable and must be administered exactly as prescribed. IV administration must occur as a slow injection or infusion over 30 to 40 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Study Design and Pain Measurements

Research has been the subject of research examining pain measurements. The drug's profile includes two intended areas of action. Studies have reported findings that included patient-reported pain scores in both acute and chronic settings.

  • Acute Pain Studies: In studies, the average difference in 0–10 Visual Analog Scale (VAS) scores between the group receiving the drug and the placebo group was recorded as 3 points. Furthermore, evidence from one study indicated that acute flares were included in the evaluation of participant status changes shortly following administration.
  • Chronic Pain Studies: Studies examined whether the drug influenced the frequency and severity of migraine attacks. Long-term data from open-label extension studies followed participants for up to one year of continuous use, examining tolerability and observed outcomes.

Systematic Reviews and Comparative Data

Meta-analyses of 12 randomized controlled trials (RCTs) analyzed the data collected in studies for moderate-to-severe pain. The research included the evaluation of comparative data against treatments targeting a single pathway.

  • Interaction Studies: Studies explored potential interactions with high-dose alcohol.
  • Emerging Research: Preliminary data reported findings from studies that included individuals with neuropathic pain. Research to fully characterize these preliminary findings is ongoing.

Key Studies & References Label: EQUALINE DUAL ACTION PAIN RELIEVER- acetaminophen, ibuprofen tablet, film coated (FDA DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Synergal (FAQ)


Q: Is Synergal the same type of medicine as [similar-sounding drug]?

Synergal is officially classified as a β-lactam/β-lactamase inhibitor combination antibiotic. This classification is based on its two active ingredients and how they function together to kill bacteria and overcome certain forms of resistance. The classification is used to define and distinguish Synergal from other antibiotics, which may operate through different mechanisms.


Q: What should I do if I accidentally miss a dose of Synergal?

Official instructions state that if a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the subsequent dose. If it is nearly time for the next dose, the missed dose should be skipped entirely. Doses are officially mandated not to be doubled to compensate for a missed one.


Q: Why is the research evidence for Synergal sometimes described as 'limited' or 'ongoing'?

Regulatory reviews and official labeling may use terms like 'ongoing' or 'preliminary' when new studies are being conducted, such as gathering long-term data on tolerability or investigating the drug's use in different patient populations. This language reflects the continuous process of gathering and reviewing research to fully characterize the medicine’s profile in every possible context.


Q: Can Synergal be cut or crushed if I have trouble swallowing pills?

Most standard immediate-release tablets are intended to be swallowed whole. Altering the tablet (cutting or crushing) can impact how the drug is absorbed, which may affect its consistency. Liquid forms (oral suspension) are manufactured specifically for patients with swallowing difficulties. The official instructions should be consulted for details on handling your specific dosage form.


Q: What is the shelf life or expiry expectation for Synergal?

The manufacturer-assigned shelf life for the tablets or dry powder is typically based on stability testing and is often several years when stored at controlled room temperature. However, once the powder is mixed to create the oral suspension, official requirements state it must be refrigerated and discarded after a set number of days, typically 10 days, to adhere to official stability requirements.


Q: How do doctors monitor the effects of Synergal?

Official safety documents outline that monitoring may include checks for liver function, renal function, and coagulation time, particularly for patients with pre-existing conditions or those on prolonged courses of treatment. Regular observation for signs of adverse reactions is consistent with official safety summaries.


Q: Can I take Synergal if I have kidney issues?

Official information confirms that patients with kidney impairment (renal impairment) require specific dose adjustments, which must be based on the degree of kidney function, such as the calculated Creatinine Clearance (CrCl). Furthermore, certain high-dose or extended-release forms are restricted for use in cases of severe kidney impairment.


Q: Is it true that Synergal is a 'once-a-day' medicine?

No, according to the official product information, Synergal is typically prescribed on an every 8-hour or 12-hour schedule depending on the specific tablet strength and the infection being treated. Following this consistent schedule is important for maintaining the correct concentration of the medicine in the body.


Q: Are there different strengths or formulations of Synergal available?

Yes, official drug labels show that Synergal is available in multiple strengths of tablets (e.g., 500 mg/ 125 mg, 875 mg/ 125 mg) and as a dry powder that is mixed to form an oral suspension. Due to differences in the ratio of active ingredients, certain strengths and dosage forms are not interchangeable.


Q: Does Synergal require any special monitoring or lab tests?

Monitoring is often necessary for patients with certain risk factors, such as those with existing kidney or liver impairment, and for patients taking oral anticoagulants. Official safety summaries also recommend attention to disturbances in blood glucose. These checks align with the potential adverse effects described in regulatory documentation.


Q: Are generic versions of Synergal available, and are they the same as the brand name?

Generic versions containing the same active ingredients (Amoxicillin and Clavulanic Acid) have been approved by government agencies for use. However, regulatory documents caution that some strengths or specific formulations are not interchangeable with others. The use of the medicine should align with the specific form prescribed.


Q: Is a prescription always required for Synergal?

Yes, Synergal (Amoxicillin and Clavulanic Acid) is officially classified as a prescription-only medicine by government regulatory bodies. This classification means it is only dispensed by a pharmacy upon authorization from a qualified healthcare professional.


Q: Does Synergal cause weight changes?

While less common than other effects, unusual weight loss has been described in association with the use of this medicine. Regulatory safety information indicates that this should be brought to the attention of a healthcare professional as it may be a potential symptom of a severe adverse reaction.


Q: Is Synergal addictive or habit-forming?

No, official drug classifications and pharmacology studies confirm that Synergal is an antibiotic. It is not classified as a controlled substance and does not act on the central nervous system pathways that are responsible for addiction or habit-forming behavior.


Q: Will I need to take Synergal long-term?

Official regulatory prescribing rules generally specify that the course of therapy should not exceed 14 days without a full clinical re-evaluation. This indicates that Synergal is typically used for short-term treatment of acute bacterial infections, not for long-term continuous use.


Q: Does taking Synergal make other medications less effective?

Official regulatory documents acknowledge potential interactions where this medicine may impact other drugs. For instance, the Amoxicillin component has been reported to possibly reduce the efficacy of oral contraceptives (birth control pills). The 'Interactions' section of the product information provides a descriptive list of known interaction patterns.


Q: What are the rules regarding Synergal and blood donation?

Official guidelines from blood donation centers generally do not restrict donation based on taking this specific antibiotic itself. Instead, eligibility is often tied to having an active bacterial infection. Donors are typically advised to wait until they have finished their course of treatment and are symptom-free before donating.


Q: What happens if I forget to take Synergal for a few days?

The official dosing schedule (every 8 or 12 hours) is designed to maintain consistent levels of the drug in your body to effectively fight the infection. While instructions exist for a single missed dose, skipping the medicine for multiple days is not addressed by that single missed dose instruction and may impact the effectiveness of the treatment course.


Q: Can Synergal cause sleep problems or insomnia?

Yes, difficulty sleeping or insomnia is listed among the commonly reported side effects in the medicine's official safety documentation. If this side effect is noted, consulting a healthcare professional is consistent with regulatory advice for adverse reactions.


Q: Is it possible to take Synergal at night instead of the morning?

The required timing is based on a fixed 8-hour or 12-hour schedule and the mandate that it be taken at the start of a meal. The specific time of day (morning or night) depends entirely on the schedule prescribed to ensure the doses are spaced correctly and taken with food.


Q: Does Synergal work immediately upon taking it?

While the medicine does not produce an immediate change in symptoms, the active components are absorbed and enter the bloodstream relatively quickly after administration. Official pharmacokinetic data indicates the concentration of the components reaches a peak in the plasma within approximately one to two hours.

How should Synergal be stored and disposed of?

How to Store and Dispose of Synergal?

The official storage requirements for Synergal (Amoxicillin and Clavulanate Potassium) depend on the medicine's form.

Storage Conditions

The tablets and dry powder for suspension must be stored at controlled room temperature, typically between 20 C and 25 C. The product must be kept in its original container, tightly closed, and protected from moisture and excessive heat.

Once the oral suspension is mixed, it requires refrigeration between 2 C and 8 C and must not be frozen. The constituted suspension must be discarded after 10 days of refrigerated storage.

Handling and Disposal

All forms of the medication must be stored out of the sight and reach of children. Unused or expired Synergal should be disposed of through a dedicated medicine take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, sealed, and thrown in the household trash; it must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Synergal found in:

A-Z Index: